Medication utilization for patients with chronic rhinosinusitis with nasal polyposis and asthma in 12 months pre- and post-dupilumab initiation.

Authors

• Emily Garvey
• Bita Naimi
• Alexander Duffy
• Chase Kahn
• Douglas Farquhar
• Marc Rosen
• Mindy Rabinowitz
• Damaris Pena Evertz
• Jessica Most
• Elina Toskala
• Gurston G Nyquist

Publication/Presentation Date

8-1-2024

Abstract

This study examines the impact of dupilumab on medication use for chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma patients. Patients on dupilumab had a reduction in oral/inhaled/topical steroids, antibiotics, and leukotriene receptor antagonists (LTRAs). The reduction in medication use had no impact on total polyp or SNOT-22 scores.

Volume

14

Issue

8

First Page

1399

Last Page

1401

ISSN

2042-6984

Published In/Presented At

Garvey, E., Naimi, B., Duffy, A., Kahn, C., Farquhar, D., Rosen, M., Rabinowitz, M., Evertz, D. P., Most, J., Toskala, E., & Nyquist, G. G. (2024). Medication utilization for patients with chronic rhinosinusitis with nasal polyposis and asthma in 12 months pre- and post-dupilumab initiation. International forum of allergy & rhinology, 14(8), 1399–1401. https://doi.org/10.1002/alr.23340

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

38409897

Department(s)

Administration and Leadership

Document Type

Article